These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10770193)

  • 21. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
    Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment.
    Kriström B; Jansson C; Rosberg S; Albertsson-Wikland K
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2889-98. PubMed ID: 9284715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers.
    de Boer H; Blok GJ; Popp-Snijders C; Stuurman L; Baxter RC; van der Veen E
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1371-7. PubMed ID: 8636336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
    Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
    Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
    Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.
    Iglesias P; Díez JJ; Fernández-Reyes MJ; Méndez J; Bajo MA; Aguilera A; Selgas R
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):741-9. PubMed ID: 15163339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure.
    Giustina A; Volterrani M; Manelli F; Desenzani P; Poiesi C; Lorusso R; Giordano A
    Am Heart J; 1999 Jun; 137(6):1035-43. PubMed ID: 10347328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy.
    Broglio F; Benso A; Arvat E; Aimaretti G; Gottero C; Granata R; Boghen MF; Bobbio M; Camanni F; Ghigo E
    J Endocrinol Invest; 2000 Sep; 23(8):520-5. PubMed ID: 11021768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
    Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary growth hormone (GH), insulin-like growth factor I (IGF-I), and IGF-binding protein-3 measurements in the diagnosis of adult GH deficiency.
    Gill MS; Toogood AA; O'Neill PA; Thorner MO; Shalet SM; Clayton PE
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2562-5. PubMed ID: 9661643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of insulin-like growth factor-1 and insulinlike growth factor binding protein-3 in diagnosis of growth hormone deficiency in short-stature children.
    Ali A; Hashim R; Khan FA; Sattar A; Ijaz A; Manzoor SM; Younas M
    J Ayub Med Coll Abbottabad; 2009; 21(3):40-5. PubMed ID: 20929010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dehydroepiandrosterone supplementation in women with adrenal failure: impact on twenty-four hour GH secretion and IGF-related parameters.
    Christiansen JJ; Gravholt CH; Fisker S; Svenstrup B; Bennett P; Veldhuis J; Andersen M; Christiansen JS; Jørgensen JO
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):461-9. PubMed ID: 15049961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significant increase of IGF-I concentration and of IGF-I/IGFBP-3 molar ratio in generation test predicts the good response to growth hormone (GH) therapy in children with short stature and normal results of GH stimulating tests.
    Smyczynska J; Hilczer M; Stawerska R; Lewinski A
    Neuro Endocrinol Lett; 2013; 34(3):222-8. PubMed ID: 23685421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport.
    Wallace JD; Cuneo RC; Baxter R; Orskov H; Keay N; Pentecost C; Dall R; Rosén T; Jørgensen JO; Cittadini A; Longobardi S; Sacca L; Christiansen JS; Bengtsson BA; Sönksen PH
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3591-601. PubMed ID: 10523001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.